Arcturus Therapeutics Announces Clinical Trial Timeline for its COVID-19 Vaccine
Arcturus Therapeutics Holdings Inc. (ARCT)
Last arcturus therapeutics holdings inc. earnings: 3/11 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.arcturusrx.com/investor-relations
Company Research
Source: GlobeNewswire
GMP-Manufactured Batch to be Delivered in June 2020 Human Dosing Expected to Begin in Summer 2020 SAN DIEGO, April 09, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics (the “Company”, NASDAQ: ARCT), a leading messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines, today announced plans to initiate a human clinical trial this Summer for its COVID-19 vaccine, also known as LUNAR-COV19. Under the guidance of the Singapore Health Sciences Authority (HSA), the trial plans to enroll up to 76 healthy volunteer adults including elderly individuals, with follow-up over several months to evaluate extent and duration of immune response. “Arcturus had a very productive meeting with the HSA where the clinical development plan was discussed in detail. We foresee continuing to work with the HSA in a collaborative fashion as we approach initiation of the first clinical trial,” said Joseph Payne, President & CEO
Show less
Read more
Impact Snapshot
Event Time:
ARCT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARCT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARCT alerts
High impacting Arcturus Therapeutics Holdings Inc. news events
Weekly update
A roundup of the hottest topics
ARCT
News
- Arcturus Therapeutics to Attend Upcoming Investor ConferenceBusiness Wire
- Arcturus Therapeutics (NASDAQ:ARCT) had its price target lowered by analysts at Citigroup Inc. from $12.00 to $9.00. They now have a "neutral" rating on the stock.MarketBeat
- Arcturus Therapeutics (NASDAQ:ARCT) had its price target lowered by analysts at Piper Sandler from $140.00 to $72.00. They now have an "overweight" rating on the stock.MarketBeat
- Arcturus Therapeutics (NASDAQ:ARCT) had its price target lowered by analysts at HC Wainwright from $12.00 to $9.00. They now have a "neutral" rating on the stock.MarketBeat
- Arcturus Therapeutics Holdings Inc (ARCT) Q3 2025 Earnings Call Highlights: Navigating ... [Yahoo! Finance]Yahoo! Finance
ARCT
Earnings
- 11/10/25 - Beat
ARCT
Sec Filings
- 11/14/25 - Form SCHEDULE
- 11/13/25 - Form SCHEDULE
- 11/12/25 - Form 10-Q
- ARCT's page on the SEC website